Preview Mode Links will not work in preview mode

 

Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.

Popular Topics

  • Virtual and digital health
  • Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
  • Value-based healthcare 
  • Precision and stratified medicine
  • Integration of digital technology into existing workflow and procedures 
  • Next-generation immuno, cell, and gene therapies
  • Vaccines
  • Biomarkers, sequencing, and imaging
  • Rare diseases
  • MedTech and medical devices
  • Clinical trials
  • Addressing Social Determinants of Health
  • Treating chronic conditions like obesity and pain
  • Clinician and staff burnout

The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors. 

 

Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.

Empowered Patient Solutions

Sep 4, 2018

Dr. Niels Riedemann, Co-founder and CEO of InflaRx, discusses the pervasive problem of inflammation in a host of diseases, and how InflaRx is tackling this problem with their clinical-stage antibody therapy, IFX-1. InflaRx believes that they have found the key to addressing inflammation across a range of diseases, in the form of a molecule in the blood, complement factor C5a. Their main focus is on using IFX-1, a monoclonal antibody, to block C5a and prevent its action in patients with hidradenitis suppurativa (HS), a devastating autoimmune disorder that manifests on the skin, to reduce inflammatory lesions and potentially prove an ability of IFX-1 to work in different inflammatory conditions.

#inflammation #InflaRx #complementsystem #HS #immunology #IFX1

InflaRx.com